Number of pages: 100 | Report Format: PDF | Published date: April 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global influenza diagnostics market was valued at US$ 1.1 billion in 2022 and is expected to register a revenue CAGR of 3.7% to reach US$ 1.52 billion by 2031.
Influenza Diagnostics Market Fundamentals
Influenza, commonly known as the flu, is a contagious respiratory illness caused by the influenza virus. The virus can infect the nose, throat, and lungs and cause mild to severe illness; in some cases, it can be fatal. Influenza diagnostics refers to the methods and tools used to diagnose the presence of the influenza virus in a person’s body. Influenza is a highly contagious respiratory illness caused by the influenza virus, and accurate diagnosis is important to initiate appropriate treatment and prevent the spread of the virus to others. Influenza is typically more severe than the common cold and can lead to complications such as pneumonia, bronchitis, and sinus and ear infections.
Influenza Diagnostics Market Dynamics
The increasing prevalence of influenza is one of the primary drivers of the growth of the global influenza diagnostics market. For instance, according to the WHO’s factsheet of January 2023, there are about 3 to 5 million cases of severe illness globally and between 290,000 and 650,000 respiratory deaths. Developing new and advanced diagnostic technologies has also been a major driver of the influenza diagnostics market. The emergence of molecular diagnostic techniques, such as polymerase chain reaction (PCR), has greatly improved the accuracy and speed of influenza diagnosis. Moreover, government initiatives aimed at controlling the spread of influenza have also contributed to the growth of the influenza diagnostics market. There is growing awareness among healthcare professionals and the general public about the importance of early diagnosis of influenza. Early diagnosis can help prevent the spread of the virus and improve patient outcomes. Furthermore, there is a growing demand for point-of-care testing (POCT) for influenza diagnosis, particularly in resource-limited settings. POCT devices are portable, easy to use, and provide rapid results, making them an attractive option for healthcare providers in these settings.
However rapid diagnostic tests (RDTs) are commonly used for influenza diagnosis, but they have limited accuracy compared to more advanced diagnostic techniques such as PCR. False negatives and positives can occur, which may result in inappropriate treatment and the spread of the virus. Moreover, in some regions, there is still a lack of awareness about the importance of influenza diagnosis, leading to lower demand for diagnostic tests. While molecular diagnostic techniques such as PCR offer greater accuracy, they can be more expensive than other diagnostic methods, which may limit their adoption, particularly in resource-limited settings. Additionally, competition from alternative diagnostic methods and the high cost of advanced diagnostic techniques are some restraints impeding the overall market revenue growth.
Influenza Diagnostics Market Ecosystem
The global influenza diagnostics market is analyzed from three perspectives: test type, end user, and region.
Influenza Diagnostics Market by Test Type
Based on the test type, the global influenza diagnostics market is segmented into traditional diagnostic tests and molecular diagnostic assays.
The traditional diagnostic test segment dominated the market with the principal revenue share in 2022. The traditional diagnostic test includes methods of influenza diagnosis that have been used for many years, including rapid influenza diagnostic test (RIDT), viral culture, direct fluorescent antibody (DFA) test, and serological assay. Rapid influenza diagnostic test (RIDT) is a diagnostic test used to detect influenza virus antigens in respiratory specimens such as nasal or throat swabs. RIDTs use immunochromatographic technology to detect the presence of viral antigens in a patient’s respiratory specimen. This involves antibodies that bind to influenza virus antigens, resulting in a visible line or signal on a test strip or device. RIDTs are designed to provide rapid results, typically within 15 to 30 minutes of specimen collection. They are relatively simple to perform and can be used at the point of care, such as in a physician’s office or a clinic.
Similarly, Viral culture involves the growth of the influenza virus in cultured cells, such as Madin-Darby canine kidney (MDCK) cells or Vero cells. This method is highly specific and can provide information on the virus subtype and strain, but it is relatively slow, with results taking several days to a week. These aspects contribute to the revenue growth of the traditional diagnostic test segment.
The molecular diagnostic assay is expected to be the fastest-growing segment during the forecast period, owing to increasing demand for accurate and rapid influenza diagnosis, particularly in the context of outbreaks and pandemics. The molecular diagnostic assay includes methods of influenza diagnosis that involve the detection of viral nucleic acids using molecular techniques such as reverse transcription polymerase chain reaction (RT-PCR) and nucleic acid amplification tests (NAATs), Nucleic Acid Sequence-based Amplification (NASBA) Test, Loop-mediated Isothermal Amplification-based Assay (LAMP), Simple Amplification-based Assay (SAMBA). These highly sensitive and specific methods allow for the rapid and accurate detection of influenza virus in respiratory specimens such as nasal or nasopharyngeal swabs. RT-PCR is the most used method in molecular diagnostic assays for influenza, and it can detect influenza viral RNA within hours of specimen collection.
In NASBA, a specific segment of RNA from the virus is amplified by using a set of primers and enzymes, producing many copies of the RNA segment. This process is carried out under isothermal conditions, meaning the amplification can occur at a single temperature, making the test relatively simple and fast to perform. The amplified RNA is then detected using various methods, such as fluorescent probes, enzyme-linked probes, or gel electrophoresis. These aspects contribute to the growth of the molecular diagnostic assay segment.
Influenza Diagnostics Market by End User
Based on the end user, the global influenza diagnostics market is segmented into Hospitals, POCTs, Laboratories, and others.
The hospital segment is a key player in the influenza diagnostics market, with the largest revenue share in 2022. Hospitals provide diagnostic and treatment services for patients with influenza. Hospitals are one of the primary end-user of influenza diagnostics, as they are often the first point of contact for patients with flu-like symptoms. Hospitals use various diagnostic methods for influenza, including rapid diagnostic tests, molecular diagnostic tests such as RT-PCR, and cell culture. The choice of diagnostic method depends on factors such as the availability of resources, the urgency of diagnosis, and the accuracy required. These overall factors contribute to the growth of the hospital segment.
The POCTs (Point of Care Testing) segment is expected to be the fastest-growing segment during the forecast period. POCT refers to rapid diagnostic tests that can provide results within minutes to hours, allowing for rapid diagnosis and treatment of patients with influenza-like symptoms. POCT for influenza typically involves using lateral flow immunoassays (LFIAs), which detect viral antigens in respiratory specimens such as nasal swabs or nasopharyngeal swabs. LFIAs are easy to use and require minimal training, making them well-suited for use in non-laboratory settings. These overall factors contribute to the revenue growth of the POCT (Point of Care Testing) segment.
Influenza Diagnostics Market by Region
Based on region, the global influenza diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global influenza diagnostics market with the largest revenue share in 2022, attributed to the increased government monitoring together with the presence of crucial actors. Additionally, companies across the region are continuously involved in launching new and innovative diagnostic procedures, which are also expected to improve the influenza diagnostics market outlook. For instance, in June 2022, BD (Becton, Dickinson, and Company), a leading global medical technology company, announced that the BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV), has been CE marked to the IVD directive 98/79/EC. The test employs a single nose swab or a single nasopharyngeal swab sample to identify whether a patient has COVID-19, the flu, or RSV. It reduces the need for several tests or medical visits and can assist physicians in promptly implementing the appropriate treatment approach. The co-testing technique also helps to enhance testing capacity during the hectic flu season and shortens the time to diagnosis.
Influenza Diagnostics Market Competitive Landscape
The prominent players operating in the global influenza diagnostics market are:
Influenza Diagnostics Market Strategic Developments
The global influenza diagnostics market was valued at US$ 1.1 billion in 2022.
Influenza diagnostics refers to the methods and tools used to diagnose the presence of the influenza virus in a person’s body.
The expected size of the global influenza diagnostics market in 2031 is US$ 1.58 billion.
The expected revenue CAGR of the influenza diagnostics market during the forecast period is 3.7% from 2023 to 2031.
Some prominent players operating in the global influenza diagnostics market are F. Hoffmann-LA Roche AG, Thermo Fisher Scientific, Inc., Hologic, Inc., 3M Company, and Abbott Laboratories, Inc.
*Insights on financial performance are subject to the availability of information in the public domain